Laronidase (Aldurazyme)

Aldurazyme (laronidase) is covered only for FDA‑approved MPS I indications (Hurler, Hurler‑Scheie, and Scheie with moderate‑to‑severe symptoms) and uses outside those indications (e.g., Scheie with mild symptoms) are not covered. Coverage requires confirmed diagnosis by deficient α‑L‑iduronidase activity (leukocytes, fibroblasts, plasma or serum) or molecular genetic testing, prescription by or consultation with a geneticist/endocrinologist/metabolic‑disorder or lysosomal‑storage‑disorder specialist, dosing ≤0.58 mg/kg IV no more than once weekly, and authorization is granted for 12 months.

"Aldurazyme (laronidase) is indicated for the treatment of individuals with the Hurler or Hurler-Scheie forms of mucopolysaccharidosis type I."

Sign up to see full coverage criteria, indications, and limitations.